v3.26.1
Segment Information (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
USD ($)
segment
Mar. 31, 2025
USD ($)
Segment Information    
Number of reportable segment | segment 1  
Revenue   $ 10,000
Research and development expenses $ 60,439 34,915
General and administrative 16,911 12,415
Stock-based compensation 9,195 5,386
Net loss (80,987) (33,573)
Zenas BioPharma (HK) Limited    
Segment Information    
Revenue 0 10,000
Single Reportable Segment    
Segment Information    
Revenue   10,000
General and administrative 10,812 8,610
Stock-based compensation 9,195 5,386
Other segment items 3,637 (3,757)
Net loss $ (80,987) $ (33,573)
Other segment items, description Other segment items consist of other (income) expense, net, and income tax (benefit) provision. Other (income) expense, net consists of interest income, interest expense related to the royalty obligation and the senior secured term loan and convertible senior note as well as realized and unrealized gains and losses on foreign currency transactions Other segment items consist of other (income) expense, net, and income tax (benefit) provision. Other (income) expense, net consists of interest income, interest expense related to the royalty obligation and the senior secured term loan and convertible senior note as well as realized and unrealized gains and losses on foreign currency transactions
Single Reportable Segment | Obexelimab    
Segment Information    
Research and development expenses $ 31,760 $ 23,491
Single Reportable Segment | Orelabrutinib    
Segment Information    
Research and development expenses 10,101  
Single Reportable Segment | Other programs (ZB002, ZB004, ZB014, ZB021 & ZB022)    
Segment Information    
Research and development expenses 568 203
Single Reportable Segment | Partnered regional programs (ZB001 & ZB005)    
Segment Information    
Research and development expenses   99
Single Reportable Segment | Unallocated    
Segment Information    
Research and development expenses $ 14,914 $ 9,541